

Richa Parikh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9806529/publications.pdf>

Version: 2024-02-01

13
papers

67
citations

1936888

4
h-index

1588620

8
g-index

13
all docs

13
docs citations

13
times ranked

165
citing authors

#	ARTICLE	IF	CITATIONS
1	A comprehensive review of the impact of obesity on plasma cell disorders. <i>Leukemia</i> , 2022, 36, 301-314.	3.3	18
2	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 808-817.	2.5	14
3	Coronary Artery Calcium Scoring in Young Adults: Evidence and Challenges. <i>Current Cardiology Reports</i> , 2018, 20, 10.	1.3	10
4	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4019.	1.7	9
5	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. <i>Journal of Clinical Medicine</i> , 2022, 11, 1640.	1.0	6
6	Late Relapsing Multiple Myeloma 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. <i>Blood</i> , 2020, 136, 11-12.	0.6	3
7	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. <i>Haematologica</i> , 2021, 106, 0-0.	1.7	2
8	Spectrum of Second Primary Malignancies in Pediatric and Adult Langerhans Cell Histiocytosis Cases. <i>Blood</i> , 2020, 136, 51-52.	0.6	2
9	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. <i>Blood</i> , 2020, 136, 44-44.	0.6	2
10	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20031-e20031.	0.8	1
11	Variation in High-Intensity Statin Use After Hospitalization for Acute Vascular Emergencies. <i>American Journal of the Medical Sciences</i> , 2018, 356, 501-502.	0.4	0
12	Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT. <i>Blood</i> , 2020, 136, 24-24.	0.6	0
13	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. <i>Haematologica</i> , 2021, , .	1.7	0